Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | IKBKB | O14920 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | AKT2 | P31751 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.53 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575589 | 1.00 | NPC1 (0.60) | NPC1IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL8106433 | 1.00 | NPC1 (0.60) | NPC1IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL14464102 | 0.88 | NPC1 (0.60) | NPC1IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL5465409 | 0.75 | NPC1 (1.00) | NPC1AKT1KDRMAP2K1PRKAA1 | |
| SCHEMBL5465411 | 0.75 | NPC1 (1.00) | NPC1AKT1KDRMAP2K1PRKAA1 | |
| SCHEMBL3567966 | 0.75 | NPC1 (1.00) | NPC1AKT1KDRMAP2K1PRKAA1 | |
| SCHEMBL16543012 | 0.73 | NPC1 (0.66) | NPC1IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL19462845 | 0.72 | STK17B (0.63) | MAPK1AKT1KDRPRKAG1PRKAA1 | |
| SCHEMBL29226048 | 0.72 | NPC1 (0.63) | NPC1IKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL8778476 | 0.70 | TUBB4A (0.52) | MAPK1MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842705-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | EMORY UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-7371766-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | disclosed |
| EP-1242379-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | Emory University (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040188-A9 | CURCUMIN ANALOGUES FOR TREATING CANCER | UNIV EMORY (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | disclosed |
| WO-2001040188-A1 | CURCUMIN ANALOGUES FOR TREATING CANCER | EMORY UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | NPC1 3599/4885IKBKB 178/4885RAF1 4090/4885 |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | PGF, VEGFA, VHL | NPC1 3599/4885IKBKB 178/4885RAF1 4090/4885 |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | NPC1 3599/4885IKBKB 178/4885RAF1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.